Metoclopramide and enteral nutritio
Phase 3
- Conditions
- Gastroparesis.Malabsorption due to intolerance, not elsewhere classified
- Registration Number
- IRCT201601213449N20
- Lead Sponsor
- Vice Chancellor for Research, Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Critically ill adult patients who are candidate to receive metoclopramide as prokinetic agent due to enteral feeding intolerance (defined as gastric residual volume equal to or greater than 250 ml concomitant with symptoms of nausea, vomiting, and regurgitation or gastric residual volume more than 500 ml during 24 hours of enteral feeding) will be included.
Exclusion criteria: Patients with metoclopramide allergy; metoclopramide intolerance; uncontrolled ventricular arrhythmia; extrapyramidal reactions; seizure; head trauma; signs and symptoms of increased intracranial pressure
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Enteral feeding intolerance. Timepoint: Daily. Method of measurement: Gastric residual will be measured between the enteral feeding intervals. Intolerance defined as gastric residual volume more than 250 ml with clinical symptoms or gastric residual volume more than 500 ml by itself.
- Secondary Outcome Measures
Name Time Method Metoclopramide side effects. Timepoint: Daily. Method of measurement: Patients will be monitored regarding metoclopramide related adverse reactions including cardiovascular (blood pressure and cardiac rhythm), neurological (extrapyramidal signs and seizure) and gastrointestinal (diarrhea).